Cytokinetics Inc
CYTKHealthcare|Biotechnology|USA
$84.87
-1.18 (-1.37%)
Clinical Trials (46)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07600177 Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy (HCM) | P4 | Recruiting | 40 | Open-label | Aficamten |
| NCT06412666 A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | P2P3 | Recruiting | 55 | RCT, Double-blind | Aficamten, Placebo |
| NCT06736574 Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Heart Failure, Heart Failure With Reduced Ejection Fraction | P3 | Recruiting | 1,800 | RCT, Double-blind | Omecamtiv Mecarbil (OM), Placebo |
| NCT06081894 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | P3 | Active | 500 | RCT, Double-blind | Aficamten, Placebo |
| NCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | P2 | Recruiting | 60 | RCT, Double-blind | CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586 |
| NCT07054073 HCMR Re-Imaging Study | Hypertrophic Cardiomyopathy (HCM) | Recruiting | 314 | — | — | |
| NCT04464525 Omecamtiv Mecarbil Post-trial Access Study | Chronic Heart Failure With Reduced Ejection Fraction | P3 | Withdrawn | — | Open-label | Omecamtiv mecarbil |
| NCT04944784 A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P3 | Terminated | 489 | RCT, Double-blind | Reldesemtiv, Placebo |
| NCT05442775 A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | Amyotrophic Lateral Sclerosis | P3 | Terminated | 71 | Open-label | Reldesemtiv |
| NCT05767346 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | Obstructive Hypertrophic Cardiomyopathy (oHCM) | P3 | Completed | 175 | RCT, Double-blind | Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate |
| NCT02936635 A Study for Patients Who Completed VITALITY-ALS (CY 4031) | Amyotrophic Lateral Sclerosis (ALS) | P3 | Completed | 280 | Open-label | tirasemtiv |
| NCT04848506 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | Symptomatic Hypertrophic Cardiomyopathy (HCM) | P2P3 | By Invite | 900 | Open-label | Aficamten (5 - 20 mg) |
| NCT03759392 Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure | Heart Failure With Reduced Ejection Fraction | P3 | Completed | 276 | RCT, Double-blind | Omecamtiv Mecarbil, Placebo |
| NCT02929329 Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction | Heart Failure | P3 | Completed | 8,256 | RCT, Double-blind | Omecamtiv Mecarbil, Placebo, Standard of Care |
| NCT02496767 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year | Amyotrophic Lateral Sclerosis | P3 | Completed | 744 | RCT, Double-blind | Tirasemtiv, Placebo tablets |
| NCT05186818 Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | Obstructive Hypertrophic Cardiomyopathy (oHCM) | P3 | Completed | 282 | RCT, Double-blind | Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten |
| NCT02662582 A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease (COPD) | P2 | Completed | 46 | RCT, Double-blind | Reldesemtiv, Placebo |
| NCT03160898 A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 458 | RCT, Double-blind | Reldesemtiv, Placebo |
| NCT02644668 A Study of CK-2127107 in Patients With Spinal Muscular Atrophy | Spinal Muscular Atrophy | P2 | Completed | 70 | RCT, Double-blind | Placebo, Reldesemtiv 150 mg, Reldesemtiv 450 mg |
| NCT01300013 Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF) | Heart Failure | P2 | Completed | 614 | RCT, Double-blind | Placebo, Omecamtiv mecarbil |
| NCT04219826 Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy (HCM) | P2 | Completed | 96 | RCT, Double-blind | CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274 |
| NCT01268280 Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis | Myasthenia Gravis | P2 | Terminated | 32 | RCT, Double-blind | Placebo, 250 mg CK-2017357, 500 mg CK-2017357 |
| NCT01486849 Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 27 | RCT, Double-blind | CK-2017357, Placebo, Riluzole 50 MG |
| NCT00624442 A Study of CK-1827452 Infusion in Stable Heart Failure | Heart Failure | P2 | Completed | 45 | RCT, Double-blind | CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, Placebo, Placebo, CK-1827452, Placebo, CK-1827452, CK-1827452, CK-1827452, CK-1827452 |
| NCT00343564 A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Hodgkin's Disease | P1P2 | Completed | 68 | Open-label | SB-743921, SB-743921 |
| NCT01378676 A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 49 | RCT, Double-blind | Placebo (Part A), CK-2017357 (Part A), CK-2017357 (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B), CK-2017357 (Part B), CK-2017357 (Part B) |
| NCT01131013 A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication | Intermittent Claudication, Peripheral Artery Disease | P2 | Completed | 61 | RCT, Double-blind | Placebo, 375 mg CK-2017357, 500 mg CK-2017357 |
| NCT00748579 Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency | Heart Failure | P2 | Terminated | 2 | Open-label | CK-1827452, CK-1827452 |
| NCT01089010 A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 67 | RCT, Double-blind | Placebo, 250 mg CK-2017357, 500 mg CK-2017357 |
| NCT02695420 Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction | Heart Failure With Reduced Ejection Fraction | P2 | Completed | 81 | RCT, Double-blind | 25 mg Omecamtiv Mecarbil, Placebo, 37.5 mg Omecamtiv Mecarbil, 50 mg Omecamtiv Mecarbil |
| NCT01709149 Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 711 | RCT, Double-blind | CK-2017357, Riluzole |
| NCT01077167 Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients | Heart Failure | P2 | Withdrawn | — | Open-label | Omecamtiv mecarbil |
| NCT01786512 COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure | Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction | P2 | Completed | 544 | RCT, Double-blind | Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2 |
| NCT00941681 Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure | Heart Failure | P2 | Completed | 35 | RCT, Open-label | CK-1827452, CK-1827452, CK-1827452 |
| NCT00682565 PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina | Heart Failure, Myocardial Ischemia | P2 | Completed | 94 | RCT, Double-blind | CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg capsule, CK-1827452 48 mg and 11 mg iv infusion, CK-1827452 25mg capsule, Placebo iv infusion, Placebo capsule |
| NCT03065959 A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility | Mobility Limitation | P1 | Terminated | 42 | RCT, Double-blind | reldesemtiv, Placebo |
| NCT05924815 Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | Healthy Participants | P1 | Completed | 44 | RCT, Double-blind | Aficamten, Aficamten-matching Placebo, Moxifloxacin |
| NCT05662215 A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants | Healthy Participants | P1 | Terminated | 57 | RCT, Double-blind | CK-3828136, Placebo for CK-3828136 |
| NCT04175808 Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults | QT Intervals Changes, QTc Intervals Changes | P1 | Completed | 70 | RCT, Double-blind | Omecamtiv Mecarbil (OM), Placebo, Moxifloxacin |
| NCT02601001 Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults | Healthy Volunteer | P1 | Completed | 50 | RCT, Double-blind | Omecamtiv mecarbil, Placebo |
| NCT03767855 A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects | Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects | P1 | Completed | 114 | RCT, Double-blind | CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets |
| NCT01737866 Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency | Heart Failure | P1 | Completed | 13 | Open-label | AMG 423 |
| NCT04783766 Safety, Tolerability and Pharmacokinetics Study of CK-3773274 | Obstructive Hypertrophic Cardiomyopathy, Healthy Adult Subjects | P1 | Completed | 28 | RCT, Double-blind | CK-3773274, Placebo |
| NCT00607841 A Study of Ispinesib in Metastatic Breast Cancer | Breast Neoplasms | P1 | Terminated | 16 | Open-label | Ispinesib, Ispinesib, Ispinesib |
| NCT01380223 A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers | Heart Failure | P1 | Completed | 35 | RCT, Double-blind | placebo, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil, omecamtiv mecarbil |
| NCT05877053 A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants | Healthy Participants | P1 | Completed | 102 | RCT, Double-blind | CK-4021586, Placebo for CK-4021586 |